Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus

Diabetes Care

Volumn 34, Issue 12, 2011, Pages 2521-2523

  Porcellati, Francesca ^a   Lucidi, Paola ^a   Rossetti, Paolo ^a   Candeloro, Paola ^a   Andreoli, Anna Marinelli ^a   Marzotti, Stefania ^a   Cioli, Patrizia ^a   Bolli, Geremia B ^a   Fanelli, Carmine G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; GLARGINE; LONG ACTING INSULIN;

ARTICLE; BODY MASS; CLINICAL ARTICLE; CORRELATION ANALYSIS; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HUMAN; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; AGED; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; MALE; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADIPOSITY; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 84855706171     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1064     Document Type: Article

References (10)

1. Lucidi P, Porcellati F, Rossetti P, et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care 2011;34:1312-1314
2. Campbell PJ, Carlson MG. Impact of obesity on insulin action in NIDDM. Diabetes 1993;42:405-410 (Pubitemid 23066516)
3. Gerich JE. Control of glycaemia. Baillieres Clin Endocrinol Metab 1993;7:551-586 (Pubitemid 23243426)
4. Schmid C, Krayenbühl P, Wiesli P. Increased insulin dose requirement of longacting insulin analogues in obese patients with type 2 diabetes. Diabetologia 2009;52:2668-2669
5. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-totarget trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274 (Pubitemid 44125921)
6. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucoselowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-416
7. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-1987
8. Swinnen SG, DeVries JH. Higher dose requirements with insulin detemir in type 2 diabetes: three cases and a review of the literature. Diabetes Res Clin Pract 2009;84:e24-e26
9. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twicedaily in patients with type 2 diabetes inadequately controlled on oral glucoselowering drugs. Diabetes Care 2010;33:1176-1178
10. Holleman F, Wang E, Bolli GB. Detemir is associated with a higher insulin dose compared to insulin glargine across a wide BMI range (Abstract). Diabetes 2011;60 (Suppl. 1):A287